Ghanta V K, Hiramoto N S, Soong S J, Miller D M, Hiramoto R N
Department of Biology, University of Alabama, Birmingham 35294.
Int J Neurosci. 1993 Jul-Aug;71(1-4):251-65. doi: 10.3109/00207459309000608.
It has been demonstrated that significant protection against YC8 lymphoma can be induced in mice preimmunized with normal DBA/2 spleen cells. The DBA/2 spleen cells used as an alloantigen share minor histocompatibility determinants with the YC8 tumor. Our observations showed that once tumor was present in vivo, the use of a potent tumor specific vaccine that can confer 100% protection to preimmunized animals, can help in increasing survival but can no longer produce high incidence of regression and cure. We have used this model to show that adoptive chemoimmunotherapy (ACIT) can be used to regress tumors in mice with large body burden of tumor and that combination of conditioning with ACIT appears to enhance the effectiveness of treatment. The nature of the immunity conferred by conditioned resistance might be due to cytotoxic T-lymphocytes.
已经证明，用正常的DBA/2脾细胞预先免疫的小鼠可诱导出对YC8淋巴瘤的显著保护作用。用作同种异体抗原的DBA/2脾细胞与YC8肿瘤共享次要组织相容性决定簇。我们的观察结果表明，一旦体内出现肿瘤，使用一种能为预先免疫的动物提供100%保护的强效肿瘤特异性疫苗，有助于提高生存率，但不再能产生高发生率的肿瘤消退和治愈。我们利用这个模型表明，过继性化学免疫疗法（ACIT）可用于使肿瘤负荷大的小鼠体内的肿瘤消退，并且预处理与ACIT联合似乎可增强治疗效果。条件性抗性所赋予的免疫性质可能归因于细胞毒性T淋巴细胞。
